Tag
Parmax Pharma Limited
5 articles
A significant shift in ownership is underway at Parmax Pharma, as Dhiren Shah and Sunil Shah, along with associated persons, are actively acquiring a substantial stake and seeking majority control. Through a combination of share purchase agreements, a preferential issue approved by the BSE, and an ongoing open offer, the new promoters aim to increase their holdings to over 50%. These moves, including off-market acquisitions by participant acquirers, signal a potential strategic realignment for the company and could lead to changes in board composition and future business direction. Investors should monitor the completion of these transactions and any subsequent announcements regarding the company’s strategic plans.
Parmax Pharma New Promoters Acquire 30.80% Stake
Parmax Pharma intimates BSE of proposed promoter reclassification following an open offer and share purchase agreement.
Acquirers Dhiren Shah and Sunil Shah, along with 10 PACs, acquired 11,52,450 sha
Parmax Pharma Receives BSE In-Principle Preferential Issue Approval
BSE granted in-principle approval for Parmax Pharma's preferential issue of 31.38 lakh equity shares and 21.45 lakh warrants.
The approval is subject to compliance with SEBI LODR regulations under ref
Parmax Pharma PAC Acquires 2.76% Stake Off-Market
Abhay Chinubhai Shah (PAC 8) acquired 249,394 equity shares (2.76%) of Parmax Pharma on June 18, 2026 via off-market transaction.
The acquisition was made at ₹35.00 per share from three individual sel
Parmax Pharma PAC Acquires 53,520 Shares
Rupa Sunil Shah acquired 53,520 equity shares in Parmax Pharma via off-market transaction on June 16, 2026.
Total shareholding of acquirer and PACs increased to 7,68,320 shares, representing 20.54% of
Parmax Pharma Acquirers Seek Majority Control via SPA
Acquirers led by Dhiren C. Shah and Sunil C. Shah to acquire control of Parmax Pharma through share purchase agreement, preferential allotment, and open offer.
SPA executed at ₹35 per share for 43,210